16 hours Ago By ABMN Staff
10x Genomics, Inc. ( NASDAQ:TXG – Get Free Report ) shares traded down 4% during trading on Monday . The stock traded as low as $21.
46 and last traded at $21.47. 141,491 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 1,625,669 shares.
The stock had previously closed at $22.37. Wall Street Analyst Weigh In A number of equities research analysts recently weighed in on TXG shares.
Bank of America dropped their price objective on 10x Genomics from $36.00 to $25.00 and set a “neutral” rating on the stock in a research report on Thursday, July 18th.
Guggenheim reaffirmed a “neutral” rating on shares of 10x Genomics in a research report on Tuesday, June 25th. Jefferies Financial Group raised shares of 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Monday, July 22nd.
Wolfe Research restated a “peer perform” rating on shares of 10x Genomics in a research note on Thursday, June 27th. Finally, Stifel Nicolaus reduced their price target on 10x Genomics from $53.00 to $25.
00 and set a “buy” rating on the stock in a research report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.
com, 10x Genomics currently has an average rating of “Moderate Buy” and an average target price of $31.60. View Our Latest Report on TXG 10x Genomics Price Performance 10x Genomics ( NASDAQ:TXG – Get Free Report ) last announced its quarterly earnings data on Thursday, August 8th.
The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.
15. The business had revenue of $153.10 million during the quarter, compared to analysts’ expectations of $150.
90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.
23%. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.
32 earnings per share for the current fiscal year. Insider Buying and Selling at 10x Genomics In related news, CEO Serge Saxonov sold 6,749 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.
53, for a total transaction of $152,054.97. Following the sale, the chief executive officer now directly owns 882,467 shares of the company’s stock, valued at $19,881,981.
51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink . In related news, CEO Serge Saxonov sold 6,749 shares of the business’s stock in a transaction on Thursday, August 22nd.
The shares were sold at an average price of $22.53, for a total value of $152,054.97.
Following the completion of the transaction, the chief executive officer now directly owns 882,467 shares in the company, valued at approximately $19,881,981.51. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website .
Also, CFO Justin J. Mcanear sold 2,961 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.
53, for a total transaction of $66,711.33. Following the sale, the chief financial officer now directly owns 143,242 shares in the company, valued at $3,227,242.
26. The disclosure for this sale can be found here . Over the last three months, insiders have sold 14,061 shares of company stock valued at $316,794.
10.03% of the stock is owned by insiders. Hedge Funds Weigh In On 10x Genomics Several institutional investors and hedge funds have recently modified their holdings of TXG.
Victory Capital Management Inc. grew its holdings in 10x Genomics by 24.6% in the fourth quarter.
Victory Capital Management Inc. now owns 12,738 shares of the company’s stock valued at $713,000 after purchasing an additional 2,515 shares during the period. Norges Bank purchased a new stake in 10x Genomics in the 4th quarter worth $36,262,000.
Dynamic Technology Lab Private Ltd acquired a new position in 10x Genomics during the fourth quarter worth $596,000. Balentine LLC acquired a new position in 10x Genomics during the fourth quarter worth $291,000. Finally, US Bancorp DE lifted its holdings in 10x Genomics by 19.
4% during the fourth quarter. US Bancorp DE now owns 15,212 shares of the company’s stock valued at $851,000 after purchasing an additional 2,469 shares in the last quarter. Hedge funds and other institutional investors own 84.
68% of the company’s stock. 10x Genomics Company Profile ( Get Free Report ) 10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
See Also Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter ..
